AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24766757 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SHARE intervention (n = 546 patients)
Number of subjects: 1186
Study 24766757 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 640 patients)
Number of subjects: 1186
Study 21226769 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated Jatropha platyphylla kernel meal (H-JPKM) diet
Number of subjects: 15
Study 21226769 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM) diet
Number of subjects: 15
Study 21226769 — intervention group
Group type: COMPARATOR
Intervention: Fish meal (FM) diet (Control)
Number of subjects: 15
Study 20681279 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tianxiong Powder (MTP) for 3 months
Number of subjects: 80
Study 20681279 — intervention group
Group type: COMPARATOR
Intervention: Wuzi Yanzong Pill (WYP) for 3 months
Number of subjects: 80
Study 17960809 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 288
Study 17960809 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded studies
Number of subjects: 288
Study 17960809 — intervention group
Group type: EXPERIMENTAL
Intervention: General public perspective
Number of subjects: 288
Study 16208802 — intervention group
Group type: EXPERIMENTAL
Intervention: PC 7000/EB‐Prophy
Number of subjects: 90
Study 16208802 — intervention group
Group type: EXPERIMENTAL
Intervention: PC 7000/EB17
Number of subjects: 90
Study 16208802 — intervention group
Group type: COMPARATOR
Intervention: SE
Number of subjects: 90
Study 11781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (1 gram, three times daily for 24 weeks)
Number of subjects: 70
Study 11781402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (in patients with high levels of disease activity)
Number of subjects: 70
Study 11781402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with high levels of disease activity)
Number of subjects: 70
Study 11781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 70
Study 10522614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interferon-beta
Number of subjects: 200
Study 10522614 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha-2b and ribavirin (combination therapy)
Number of subjects: 200
Study 8540716 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily) plus rifampin (900 mg/day, single morning dose for 45 days)
Number of subjects: 194
Study 8540716 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily) plus streptomycin (1 g/day, intramuscularly for 14 days)
Number of subjects: 194
Study 1771284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin 2 micrograms/kg
Number of subjects: 30
Study 1771284 — intervention group
Group type: COMPARATOR
Intervention: Control (no nitroglycerin)
Number of subjects: 30
Study 6167119 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 65
Study 6167119 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline chloride 1 g/day for one week
Number of subjects: 65
Study 30932750 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplement
Number of subjects: 12
Study 30932750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) supplement
Number of subjects: 12
Study 31801326 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes specific nutrition supplement (DSNS) along with lifestyle intervention
Number of subjects: 120
Study 31801326 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study 27082845 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with water before toothbrushing
Number of subjects: 48
Study 27082845 — intervention group
Group type: COMPARATOR
Intervention: Rinsing with water after toothbrushing
Number of subjects: 48
Study 25792132 — intervention group
Group type: EXPERIMENTAL
Intervention: Children alone
Number of subjects: 0
Study 25792132 — intervention group
Group type: COMPARATOR
Intervention: Children with bystanders present
Number of subjects: 0
Study 25792132 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with bystanders behind a barrier
Number of subjects: 0
Study 23630119 — intervention group
Group type: EXPERIMENTAL
Intervention: l-dopa/carbidopa/entacapone (LCE)
Number of subjects: 745
Study 23630119 — intervention group
Group type: COMPARATOR
Intervention: l-dopa/carbidopa (LC)
Number of subjects: 745
Study 23630119 — intervention group
Group type: EXPERIMENTAL
Intervention: l-dopa dose
Number of subjects: 745
Study 21296600 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN)
Number of subjects: 153
Study 19062112 — intervention group
Group type: COMPARATOR
Intervention: Low Sodium Intake (LSI) - matched placebo
Number of subjects: 0
Study 19062112 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Sodium Intake (NSI) - 80 mmol/day of oral sodium supplements
Number of subjects: 0
Study 16443859 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate
Number of subjects: 44
Study 16443859 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg candesartan
Number of subjects: 44
Study 16443859 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate and 16 mg candesartan (combined therapy)
Number of subjects: 44
Study 16443859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15545863 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 0
Study 15545863 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study 10904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dalteparin sodium (subcutaneous, once daily)
Number of subjects: 1472
Study 10904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative dalteparin sodium (subcutaneous, once daily)
Number of subjects: 1472
Study 10904464 — intervention group
Group type: COMPARATOR
Intervention: Warfarin sodium (postoperative)
Number of subjects: 1472
Study 9068505 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute catheterization
Number of subjects: 296
Study 9068505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue angioplasty
Number of subjects: 296
Study 9068505 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic regimen (alteplase, urokinase, or both)
Number of subjects: 296
Study 9068505 — intervention group
Group type: COMPARATOR
Intervention: Catheterization strategy (acute vs deferred)
Number of subjects: 296
Study 8378155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine at a dose of 6 mg/kg
Number of subjects: 2
Study 8378155 — intervention group
Group type: COMPARATOR
Intervention: Oral meperidine/promethazine combination at doses of 2 mg/kg and 0.5 mg/kg respectively
Number of subjects: 2
Study 3752621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick test with extracts of larval and adult midges
Number of subjects: 303
Study 3752621 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test (RAST) with extracts of larval and adult midges
Number of subjects: 303
Study 3752621 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 303
Study 30891524 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroimplantation (group H)
Number of subjects: 84
Study 30891524 — intervention group
Group type: COMPARATOR
Intervention: Viscoimplantation (group V)
Number of subjects: 84
Study 30891524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (H and V)
Number of subjects: 84
Study 26771908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) and aspirin
Number of subjects: 32
Study 26771908 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 32
Study 25574801 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 149
Study 25574801 — intervention group
Group type: COMPARATOR
Intervention: Moderate Sedation (MS)
Number of subjects: 149
Study 23786503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 4% nicotinamide
Number of subjects: 80
Study 23786503 — intervention group
Group type: COMPARATOR
Intervention: 1% clindamycin
Number of subjects: 80
Study 21955937 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg extended-release niacin for 4 weeks, then 1000 mg extended-release niacin for 4 weeks
Number of subjects: 47
Study 21955937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19000717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic condition (12.7 kPa PIO(2))
Number of subjects: 21
Study 19000717 — intervention group
Group type: COMPARATOR
Intervention: Normoxic condition (21 kPa PIO(2))
Number of subjects: 21
Study 16923416 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (n = 253)
Number of subjects: 526
Study 16923416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 273)
Number of subjects: 526
Study 15570149 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 41
Study 15570149 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 41
Study 15570149 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 41
Study 11346394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enucleation preceded by external beam radiotherapy
Number of subjects: 1003
Study 11346394 — intervention group
Group type: COMPARATOR
Intervention: Enucleation only
Number of subjects: 1003
Study 11346394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1003
Study 9214419 — intervention group
Group type: EXPERIMENTAL
Intervention: Core set of outcome variables for assessment of JA
Number of subjects: 0
Study 7641719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 4% lignocaine
Number of subjects: 0
Study 2568812 — intervention group
Group type: EXPERIMENTAL
Intervention: Iosimide
Number of subjects: 100
Study 2568812 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 100
Study 361645 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediastinoscopy (Group A)
Number of subjects: 130
Study 361645 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy (Group B)
Number of subjects: 130
Study 361645 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (Group B)
Number of subjects: 130
Study 31226187 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted implant planning and template-guided implant placement (CAIPP)
Number of subjects: 73
Study 31226187 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocols (control)
Number of subjects: 73
Study 29121061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 400 mg once daily for 3 days
Number of subjects: 70
Study 29121061 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 2500 mg total dose (1500 mg chloroquine base) over 3 days plus primaquine 15 mg daily for 14 days
Number of subjects: 70
Study 29121061 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine/primaquine
Number of subjects: 70
Study 26674119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulvers' figure rating scale
Number of subjects: 147
Study 25803763 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication therapy management reconciliation service (MRS)
Number of subjects: 0
Study 25803763 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-MRS)
Number of subjects: 0
Study 22517293 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (5 g/day) and HDEL
Number of subjects: 84
Study 22517293 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/day) and HDEL
Number of subjects: 84
Study 22517293 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine, selenium and HDEL
Number of subjects: 84
Study 22517293 — intervention group
Group type: EXPERIMENTAL
Intervention: HDEL
Number of subjects: 84
Study 22517293 — intervention group
Group type: COMPARATOR
Intervention: Control diet (HDEL)
Number of subjects: 84
Study 20683147 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CRP (top 15 percentile; CRP >= 2.09 mg/L)
Number of subjects: 3133
Study 20683147 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban region participants
Number of subjects: 3133
Study 20683147 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 3133
Study 19000538 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 mg/day
Number of subjects: 45
Study 19000538 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg/day
Number of subjects: 45
Study 19000538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no azelnidipine)
Number of subjects: 45
Study 16838827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg to 40 mg daily plus IPT 1 session weekly
Number of subjects: 39
Study 16838827 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg to 40 mg daily
Number of subjects: 39
Study 12636462 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 271)
Number of subjects: 1092
Study 12636462 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (n = 269)
Number of subjects: 1092
Study 12636462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus exercise (n = 266)
Number of subjects: 1092
Study 12636462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) alone (n = 286)
Number of subjects: 1092
Study 12636462 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT (n = 552)
Number of subjects: 1092
Study 12636462 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n = 531)
Number of subjects: 1092
Study 12636462 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone or in combination with CBT
Number of subjects: 1092
Study 12636462 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT alone
Number of subjects: 1092
Study 12636462 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither treatment
Number of subjects: 1092
Study 11028140 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program
Number of subjects: 0
Study 11028140 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 0
Study 9437561 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing rod (LNG rod)
Number of subjects: 42
Study 9437561 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant capsule implants
Number of subjects: 42
Study 9437561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 8217759 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine (Exoderil) applied twice daily for 4 weeks
Number of subjects: 269
Study 8217759 — intervention group
Group type: COMPARATOR
Intervention: 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC) applied twice daily for 4 weeks
Number of subjects: 269
Study 8217759 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine (Exoderil)
Number of subjects: 269
Study 8217759 — intervention group
Group type: COMPARATOR
Intervention: 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC)
Number of subjects: 269
Study 3330524 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (40 mg three times a day)
Number of subjects: 18
Study 3330524 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and atropine (0.2 mg kg‐1 and 0.04 mg kg‐1 respectively)
Number of subjects: 18
Study 31996370 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA ≤ 1 ng/mL
Number of subjects: 33897
Study 31996370 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 1.01-2.5 ng/mL
Number of subjects: 33897
Study 31996370 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA ≤ 0.5 ng/mL, aged ≥65 years
Number of subjects: 33897
Study 31996370 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA ≤ 1 ng/mL, black men
Number of subjects: 33897
Study 29660421 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg
Number of subjects: 0
Study 29660421 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg
Number of subjects: 0
Study 29660421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26718934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonia inhalation
Number of subjects: 15
Study 26718934 — intervention group
Group type: COMPARATOR
Intervention: Control (no ammonia inhalation)
Number of subjects: 15
Study 25037182 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 78
Study 25037182 — intervention group
Group type: COMPARATOR
Intervention: Non-PRF (control)
Number of subjects: 78
Study 22290884 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-PA conduit placement on the left side to the neo-aorta
Number of subjects: 60
Study 22290884 — intervention group
Group type: COMPARATOR
Intervention: RV-PA conduit placement on the right side to the neo-aorta
Number of subjects: 60
Study 20178050 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208
Number of subjects: 0
Study 17689192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 41
Study 17689192 — intervention group
Group type: COMPARATOR
Intervention: Control (simple relaxation)
Number of subjects: 41
Study 17689192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (highly hypnotic susceptible patients)
Number of subjects: 41
Study 17689192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (less susceptible patients)
Number of subjects: 41
Study 17689192 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 15671361 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a relaxation audiotape before and during mammography
Number of subjects: 0
Study 15671361 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a music audiotape before and during mammography
Number of subjects: 0
Study 15671361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiotape)
Number of subjects: 0
Study 12500001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Crohn's Disease Activity Index (PCDAI) in clinical practice setting
Number of subjects: 0
Study 12500001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Crohn's Disease Activity Index (PCDAI) in randomized controlled trial (RCT) setting
Number of subjects: 0
Study 12500001 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PCDAI
Number of subjects: 0
Study 12500001 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PCDAI in RCT setting
Number of subjects: 0
Study 11172797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg) and Ethinylestradiol (0.03 mg)
Number of subjects: 18
Study 11172797 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (0.125 mg) and Ethinylestradiol (0.03 mg)
Number of subjects: 18
Study 8927471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (n=19)
Number of subjects: 75
Study 8927471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (n=13)
Number of subjects: 75
Study 8927471 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (n=26)
Number of subjects: 75
Study 8927471 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (n=17)
Number of subjects: 75
Study 7971012 — intervention group
Group type: EXPERIMENTAL
Intervention: PCAT program
Number of subjects: 88
Study 7971012 — intervention group
Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 88
Study 2893635 — intervention group
Group type: EXPERIMENTAL
Intervention: Koe 3290 100 mg
Number of subjects: 14
Study 2893635 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 14
Study 2893635 — intervention group
Group type: EXPERIMENTAL
Intervention: Koe 3290
Number of subjects: 14
Study 2893635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2893635 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25, 50 and 100 mg
Number of subjects: 14
Study 2893635 — intervention group
Group type: EXPERIMENTAL
Intervention: Koe 3290 12.5, 25, 50 and 100 mg
Number of subjects: 14
Study 29325922 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO (individual, nonfacilitated 15-minute sessions, 3 afternoons per week for 10 weeks)
Number of subjects: 415
Study 29325922 — intervention group
Group type: EXPERIMENTAL
Intervention: Plush toy (as per PARO but with artificial intelligence disabled)
Number of subjects: 415
Study 29325922 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study 27540967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 80
Study 27540967 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Cognitive Training Combined (AECT)
Number of subjects: 80
Study 27540967 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Training (CT)
Number of subjects: 80
Study 27540967 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 80
Study 25551814 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block with 150 mg levobupivacaine
Number of subjects: 40
Study 25551814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no paravertebral block)
Number of subjects: 40
Study 22038338 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet training (behaviorally focused and video-based training, 2 weekly visits)
Number of subjects: 158
Study 22038338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 158
Study 20567823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospira filgrastim at 5 microg/kg
Number of subjects: 50
Study 20567823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospira filgrastim at 10 microg/kg
Number of subjects: 50
Study 20567823 — intervention group
Group type: COMPARATOR
Intervention: Amgen filgrastim at 5 microg/kg
Number of subjects: 50
Study 20567823 — intervention group
Group type: COMPARATOR
Intervention: Amgen filgrastim at 10 microg/kg
Number of subjects: 50
Study 18950331 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal blockade with levobupivacaine 0.25% 2 mg x kg(‐1)
Number of subjects: 62